Establishing a suspension culture-based lentiviral vector bioprocessing facility
Cell & Gene Therapy Insights 2020; 6(1), 103-108.
Published: 10 March 2020
Associate Director is the lead of the Vector Manufacturing Science and Technology group at Adaptimmune, UK. In 2018, Gabrielle established the team responsible for starting-up Adaptimmune’s manufacturing capabilities at the Catapult CGT Manufacturing Centre in Stevenage. Her focus is currently on the production of GMP lentiviral vector for TCR T-cell therapy. Previously she has been involved in the GMP manufacturing of lentiviral vectors for CAR T-cell therapy and for gene therapy applications. Her area of expertise is the design and delivery of cleanroom bioprocesses for novel breakthrough therapies focusing on single-use disposable flow paths, aseptic processing and data monitoring.